Live search
TopFind is fetching the latest matches for your search.
We reviewed 244 live results for kanjinti trastuzumab 440 mg vial and narrowed them down to the 3 options that look most worth comparing first.
The strongest themes across this short list are Oncology and Biosimilar.
Source: Amgen
Description
Kanjinti is a high-dose 440 mg formulation of the trastuzumab biosimilar, indicated for patients with HER2-positive breast and gastric cancers. It works as a monoclonal antibody that inhibits the growth of tumor cells overexpressing the HER2 protein. Administered only by intravenous infusion, this prescription medication is registered in Singapore (SIN16207P) and is used in both early and metastatic stages of cancer therapy. The product is a biological medicine developed to meet the same quality, safety, and efficacy standards as the reference product.
Best for
Metastatic breast cancer, High Dose trastuzumab therapy, HER2 Positive gastric cancer and Hospital Administered oncology
Rating
Source: Amgen
Description
Kanjinti is a biosimilar monoclonal antibody to the reference medicine Herceptin (trastuzumab). As a HER2/neu receptor antagonist, it is used for the treatment of HER2-overexpressing early breast cancer, metastatic breast cancer, and metastatic gastric or gastroesophageal junction adenocarcinoma. This 150 mg powder for injection vial is a prescription-only medicine (POM) typically administered via intravenous infusion in a clinical setting. It is registered in Singapore by the Health Sciences Authority (HSA) and listed in the National Drug Formulary for potential medical subsidies.
Best for
HER2 Positive cancer patients, Breast cancer treatment, Gastric adenocarcinoma patients and Oncology biosimilar cost Savings
Rating
Source: DoctorOnCall
Description
Available for online pre-order, this 440mg vial of Herzuma powder for concentrate solution for infusion is offered with international shipping options to Singapore.
Best for
Online medication ordering, Cross Border fulfillment and Price comparison
Rating
| Compare | Kanjinti (Trastuzumab) 440 mg/vial | Kanjinti (Trastuzumab) 150 mg/vial | Herzuma 440 mg (Online Pre-order) |
|---|---|---|---|
| Source | Amgen | Amgen | DoctorOnCall |
| Description | Kanjinti is a high-dose 440 mg formulation of the trastuzumab biosimilar, indicated for patients with HER2-positive breast and gastric cancers. It works as a monoclonal antibody that inhibits the growth of tumor cells overexpressing the HER2 protein. Administered only by intravenous infusion, this prescription medication is registered in Singapore (SIN16207P) and is used in both early and metastatic stages of cancer therapy. The product is a biological medicine developed to meet the same quality, safety, and efficacy standards as the reference product. | Kanjinti is a biosimilar monoclonal antibody to the reference medicine Herceptin (trastuzumab). As a HER2/neu receptor antagonist, it is used for the treatment of HER2-overexpressing early breast cancer, metastatic breast cancer, and metastatic gastric or gastroesophageal junction adenocarcinoma. This 150 mg powder for injection vial is a prescription-only medicine (POM) typically administered via intravenous infusion in a clinical setting. It is registered in Singapore by the Health Sciences Authority (HSA) and listed in the National Drug Formulary for potential medical subsidies. | Available for online pre-order, this 440mg vial of Herzuma powder for concentrate solution for infusion is offered with international shipping options to Singapore. |
| Best for | Metastatic breast cancer, High Dose trastuzumab therapy, HER2 Positive gastric cancer and Hospital Administered oncology | HER2 Positive cancer patients, Breast cancer treatment, Gastric adenocarcinoma patients and Oncology biosimilar cost Savings | Online medication ordering, Cross Border fulfillment and Price comparison |
| Action | |||
| Rating |
If you want the most balanced option to start with, I recommend:
"Kanjinti (Trastuzumab) 440 mg/vial from Amgen."
I picked this because Recommended for patients requiring a higher dosage vial of trastuzumab for HER2-overexpressing cancer therapy, featuring Singapore regulatory approval and formulary inclusion.